Related references
Note: Only part of the references are listed.CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy
Terry J. Fry et al.
NATURE MEDICINE (2018)
CRISPR/Cas9 genome editing in human hematopoietic stem cells
Rasmus O. Bak et al.
NATURE PROTOCOLS (2018)
Desensitized chimeric antigen receptor T cells selectively recognize target cells with enhanced antigen expression
Chungyong Han et al.
NATURE COMMUNICATIONS (2018)
Programming CAR-T cells to kill cancer
Louai Labanieh et al.
NATURE BIOMEDICAL ENGINEERING (2018)
Reprogramming human T cell function and specificity with non-viral genome targeting
Theodore L. Roth et al.
NATURE (2018)
Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo
Sarwish Rafiq et al.
NATURE BIOTECHNOLOGY (2018)
Tumor Antigen Escape from CAR T-cell Therapy
Robbie G. Majzner et al.
CANCER DISCOVERY (2018)
CRISPR-Cas9-mediated multiplex gene editing in CAR-T cells
Xiaojuan Liu et al.
CELL RESEARCH (2017)
Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition
Jiangtao Ren et al.
CLINICAL CANCER RESEARCH (2017)
Multiplex gene editing by CRISPR-Cpf1 using a single crRNA array
Bernd Zetsche et al.
NATURE BIOTECHNOLOGY (2017)
Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection
Justin Eyquem et al.
NATURE (2017)
Tragedy, Perseverance, and Chance - The Story of CAR-T Therapy
Lisa Rosenbaum
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
S. S. Neelapu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Global Manufacturing of CAR T Cell Therapy
Bruce L. Levine et al.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2017)
Highly efficient homology-driven genome editing in human T cells by combining zinc-finger nuclease mRNA and AAV6 donor delivery
Jianbin Wang et al.
NUCLEIC ACIDS RESEARCH (2016)
Genome-wide specificities of CRISPR-Cas Cpf1 nucleases in human cells
Benjamin P. Kleinstiver et al.
NATURE BIOTECHNOLOGY (2016)
Driving CAR T-cells forward
Hollie J. Jackson et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Genome-wide CRISPR Screen in a Mouse Model of Tumor Growth and Metastasis
Sidi Chen et al.
CELL (2015)
Cpf1 Is a Single RNA-Guided Endonuclease of a Class 2 CRISPR-Cas System
Bernd Zetsche et al.
CELL (2015)
Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma
Alfred L. Garfall et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Generation of knock-in primary human T cells using Cas9 ribonucleoproteins
Kathrin Schumann et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Gene Editing of CCR5 in Autologous CD4 T Cells of Persons Infected with HIV
Pablo Tebas et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Shannon L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia
Waleed Haso et al.
BLOOD (2013)
A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR
Hiroki Torikai et al.
BLOOD (2012)
Surrogate reporters for enrichment of cells with nuclease-induced mutations
Hyojin Kim et al.
NATURE METHODS (2011)
Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia
David L. Porter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia
Michael Kalos et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Construction and Preclinical Evaluation of an Anti-CD19 Chimeric Antigen Receptor
James N. Kochenderfer et al.
JOURNAL OF IMMUNOTHERAPY (2009)
Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients
Steven J. Howe et al.
JOURNAL OF CLINICAL INVESTIGATION (2008)
Silencing and variegation of gammaretrovirus and lentivirus vectors
J Ellis
HUMAN GENE THERAPY (2005)
Oncogenesis following delivery of a nonprimate lentiviral gene therapy vector to fetal and neonatal mice
M Themis et al.
MOLECULAR THERAPY (2005)